The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2021 | Exciting therapeutic developments on the horizon for WM
Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, discusses innovation in the field of Waldenström’s macroglobulinemia (WM). Several trials assessing promising agents are currently underway, with more novel strategies in the pipeline. Venetoclax has demonstrated meaningful activity in patients with WM, both in newly diagnosed individuals and those with prior BTK inhibition. CXCR4 antagonists are also emerging as an effective strategy, with ulocuplumab and mavorixafor showing promising preliminary data. Dr Treon also comments on antibody-drug conjugates and bispecific antibodies which are a new area of investigation in WM. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.
Disclosures
Research funding and consulting fees: Janssen, Abbvie/Pharmacyclics, Beigene, X4
Research funding: Eli Lilly
